Novo Nordisk Shares Plunge After New Obesity Shot Disappoints

Novo Nordisk’s big bet to improve on the success of its weight-loss drug franchise hit a stumbling block Friday, wiping out nearly $100 billion of the drugmaker’s stock-market value. The ...

CouponFollow Extension

$100
OFF

Novo Nordisk Shares Plunge After New Obesity Shot Disappoints

4 weeks from now

Novo Nordisk’s big bet to improve on the success of its weight-loss drug franchise hit a stumbling block Friday, wiping out nearly $100 billion of the drugmaker’s stock-market value. The ...

msn.com

$94
OFF

Novo Nordisk Shares Plunge After New Obesity Shot Disappoints

4 weeks from now

Novo Nordisk Shares Plunge After New Obesity Shot Disappoints Ozempic and Wegovy maker lost $94.5 billion in market value after releasing study results for a next-generation weight-loss …

wsj.com

20%
OFF

Novo Nordisk Shares Plunge 20% After Disappointing Trial Results; …

4 weeks from now

Dec 20, 2024 · Shares of Novo Nordisk plummeted roughly 20% on Friday. The fall comes after the Danish pharmaceutical giant reported results in a late-stage trial for its experimental …

nbcchicago.com

18%
OFF

Novo Nordisk Stock Plunges After Disappointing Obesity Drug Data

4 weeks from now

Dec 20, 2024 · Shares in Danish drugmaker Novo Nordisk NVO, known for its blockbuster drugs Ozempic and Wegovy, fell roughly 18% on Friday after the firm released the results of a …

morningstar.com

7%
OFF

Novo Nordisk Shares Plunge After CagriSema Obesity Drug Trial …

4 weeks from now

The CagriSema trial showed the drug helped patients cut their weight by 22.7%, below the 25% Novo Nordisk had expected. Novo's shares fell as much as 27% after the results were …

msn.com

7%
OFF

Novo Nordisk Shares Plunge After CagriSema Obesity Drug Trial …

4 weeks from now

Dec 21, 2024 · The CagriSema trial showed the drug helped patients cut their weight by 22.7%, below the 25% Novo Nordisk had expected. Novo's shares fell as much as 27% after the …

indiatimes.com

18%
OFF

Novo Nordisk Stock Crashes 18% After New Obesity Drug Misses …

4 weeks from now

Dec 20, 2024 · Novo Nordisk Stock Slumps. The bad news sent Novo Nordisk stock down 17.8% to 85. Shares have been falling since midyear. Eli Lilly stock rose 1.4% to 767.76, while Viking …

investors.com

$125
OFF

Novo Nordisk Shares Plunge After CagriSema Obesity Drug Trial ...

4 weeks from now

Dec 20, 2024 · Novo Nordisk on Friday revealed disappointing results in a late-stage trial for its experimental next-generation obesity drug CagriSema, wiping as much as $125 billion off its …

reuters.com

$125
OFF

Novo Nordisk Shares Plunge After CagriSema Obesity Drug Trial …

4 weeks from now

Dec 20, 2024 · STORY: Novo Nordisk saw as much as $125 billion wiped off its market value on Friday (Dec 20).Investors sold off after a weight loss drug underperformed expectations in a …

yahoo.com

20%
OFF

Novo Nordisk Faces Stock Market Bloodbath After Drug Trial …

4 weeks from now

Dec 20, 2024 · Shares in Novo Nordisk plunged 20% on Friday. Novo Nordisk faces stock market bloodbath after weight-loss drug trial disappoints

fortune.com

FAQs about Novo Nordisk Shares Plunge After New Obesity Shot Disappoints Coupon?

Why did Novo Nordisk's shares fall?

Novo Nordisk’s shares fell by the most on record after patients using its experimental obesity shot CagriSema lost less weight than predicted in a study, throwing into question the drugmaker’s ability to maintain its lead in the exploding weight-loss market. ...

Why did Novo Nordisk stock plunge?

(Photo: Reuters/Tom Little) COPENHAGEN: Shares in Danish pharmaceutical giant Novo Nordisk, maker of diabetes and weight-loss treatments Ozempic and Wegovy, plunged on Friday (Dec 20) after it announced disappointing results of a new drug study. ...

Why did Novo Nordisk lose $125 billion?

STORY: Novo Nordisk saw as much as $125 billion wiped off its market value on Friday (Dec 20). Investors sold off after a weight loss drug underperformed expectations in a late-stage trial. Novo said its experimental next-generation obesity drug CagriSema helped patients cut weight by 22.7%. But that was below the 25% mark it had expected. ...

Why did Novo Nordisk A/s's shares fall by the most on record?

(Bloomberg) -- Novo Nordisk A/S’s shares fell by the most on record after a failed attempt to leapfrog rival Eli Lilly & Co. in the red-hot market for obesity drugs. Most Read from Bloomberg ...

Why did Novo Nordisk stock tank?

Novo Nordisk's stock tanked after a highly anticipated drug trial disappointed. The study showed its new obesity drug helped people lose less weight than expected. Eli Lilly, a competitor in the market for GLP-1 weight loss drugs, was up about 5%. ...

Will Novo Nordisk improve on its weight-loss drug franchise?

Illustration: Elizabeth Smelov Novo Nordisk ’s big bet to improve on the success of its weight-loss drug franchise hit a stumbling block Friday, wiping out nearly $100 billion of the drugmaker’s stock-market value. ...